Pharmaceuticals - Indian - Bulk Drugs & Formln M/S
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 1,093.79 | 935.58 | 803.41 | 412.03 | 374.62 |
Total Expenses | 964.26 | 843.78 | 717.69 | 365.69 | 337.09 |
Profit Before Tax | 129.53 | 91.80 | 85.72 | 46.34 | 37.53 |
Profit After Tax | 94.34 | 67.95 | 63.95 | 34.50 | 27.89 |
Operating Profit after Depreciation | 150.99 | 111.77 | 91.40 | 50.27 | 42.16 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 357.88 | 182.88 | 183.03 | 79.14 | 73.16 |
Total Non Current Assets | 741.13 | 261.95 | 196.42 | 99.15 | 74 |
Total Current Assets | 579.75 | 442.47 | 379.05 | 270.46 | 171.06 |
TOTAL ASSETS | 1,320.88 | 704.41 | 575.48 | 369.62 | 245.06 |
Total Shareholder's Fund | 830.89 | 276.51 | 208.61 | 144.82 | 110.35 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | 146.34 | 67.12 | 58.90 | 41.57 | 30.80 |
Net Cash used in Investing Activities | -498.97 | -90.84 | -188.12 | -19.67 | -6.04 |
Net Cash used in Financing Activities | 360.83 | 27.09 | 124.57 | -19.34 | -23.28 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 875.65 | 867.41 | 788.31 | 412.03 | 374.62 |
Total Expenses | 781.95 | 789.10 | 699.68 | 365.69 | 337.09 |
Profit Before Tax | 93.70 | 78.31 | 88.63 | 46.34 | 37.53 |
Profit After Tax | 68.16 | 57.55 | 66.18 | 34.50 | 27.89 |
Operating Profit after Depreciation | 107.29 | 96.61 | 93.96 | 50.27 | 42.16 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 163.56 | 161.37 | 161.21 | 79.14 | 73.16 |
Total Non Current Assets | 717.63 | 299.95 | 231.63 | 99.15 | 74 |
Total Current Assets | 437.44 | 378.38 | 313.28 | 270.46 | 171.06 |
TOTAL ASSETS | 1,155.07 | 678.34 | 544.91 | 369.62 | 245.06 |
Total Shareholder's Fund | 723.72 | 268.32 | 210.83 | 144.82 | 110.35 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | 111.67 | 39.28 | 58.34 | 41.57 | 30.80 |
Net Cash used in Investing Activities | -471.55 | -87.53 | -188.33 | -19.67 | -6.04 |
Net Cash used in Financing Activities | 368.13 | 51.29 | 125.30 | -19.33 | -23.28 |
Particulars (in ₹ Cr.) | 2024-09 | 2024-06 | 2024-03 | 2023-12 | 2023-09 |
---|---|---|---|---|---|
Total Revenue | 318.20 | 294.27 | 262.63 | 302.49 | 282.94 |
Total Expenses | 268.47 | 252.10 | 224.55 | 257.89 | 242.46 |
Profit Before Tax | 46.81 | 39.30 | 39.55 | 35.21 | 30.18 |
Profit After Tax | 35 | 29.48 | 28.72 | 25.13 | 22.91 |
Operating Profit after Depreciation | 51.95 | 44.29 | 43.77 | 46.94 | 43.82 |
Particulars (in ₹ Cr.) | 2024-09 | 2024-06 | 2024-03 | 2023-12 | 2023-09 |
---|---|---|---|---|---|
Total Revenue | 240.18 | 226.83 | 198.10 | 236.46 | 211.73 |
Total Expenses | 207 | 198.38 | 174.71 | 205.94 | 185.45 |
Profit Before Tax | 34.31 | 29.94 | 26.35 | 25.51 | 20.38 |
Profit After Tax | 25.61 | 22.34 | 19.72 | 18.65 | 14.47 |
Operating Profit after Depreciation | 37.46 | 33.09 | 29.40 | 32.29 | 28.39 |
Company | Price | Market Cap (in ₹ Cr) |
---|---|---|
Innova Captab Ltd | ₹1,037.15 | ₹5,935.08 |
Sun Pharmaceuticals Industries Ltd | ₹1,761.80 | ₹4,22,714.84 |
Divis Laboratories Ltd | ₹5,818.40 | ₹1,54,460.24 |
Cipla Ltd | ₹1,427.30 | ₹1,15,270.75 |
Dr Reddys Laboratories Ltd | ₹1,288.45 | ₹1,07,511.36 |
Torrent Pharmaceuticals Ltd | ₹3,157.60 | ₹1,06,862.73 |
15 Jan 2025, 12:23 pm
14 Jan 2025, 07:43 pm
30 Oct 2024, 05:25 pm
26 Aug 2024, 02:52 pm
06 Aug 2024, 05:05 pm